Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) saw some unusual options trading on Wednesday. Investors purchased 5,176 call options on the company. This is an increase of approximately 907% compared to the typical daily volume of 514 call options.

Wall Street Analyst Weigh In

HRTX has been the subject of several research analyst reports. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Needham & Company LLC dropped their target price on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Heron Therapeutics Stock Up 5.5 %

Shares of Heron Therapeutics stock opened at $1.16 on Thursday. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The company has a market capitalization of $176.44 million, a P/E ratio of -6.44 and a beta of 1.81. The company has a 50 day moving average of $1.72 and a 200 day moving average of $2.43.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same quarter in the previous year, the firm posted ($0.17) EPS. As a group, research analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of Heron Therapeutics in the 2nd quarter valued at $27,000. HB Wealth Management LLC purchased a new stake in Heron Therapeutics in the second quarter valued at $35,000. Cutter & CO Brokerage Inc. acquired a new position in Heron Therapeutics in the third quarter valued at $39,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Heron Therapeutics during the third quarter worth about $39,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Heron Therapeutics during the second quarter worth about $41,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.